He used to travel about 85 km a day by bus to meet doctors and sell medicines across Uttar Pradesh. The same man decades later built one of India’s biggest pharmaceutical companies, exporting medicines to 34 countries and building a multi-billion dollar empire.
The story of Ramesh Juneja is not just another success story of an Indian entrepreneur. It’s a lesson in understanding under served markets, building affordable healthcare products and making bold business decisions at the right time.
From a modest beginning of ₹50 lakh and 25 salesmen, Juneja took Mankind Pharma to become India’s fourth-largest pharmaceutical company in terms of domestic sales – a story that proves how a thorough understanding of the market can trump even bigger players.
Early Life of Ramesh Juneja
Ramesh Juneja was born in a middle class family in Meerut in 1955. Unlike many billionaire founders who inherited businesses or had the backing of money, Juneja came from a modest background.
He did his science graduation and entered the pharma industry in the 1970s when the pharma market of India was still nascent and very relationship-based.
This phase set the foundation of the future Mankind Pharma founder’s business philosophy: affordable medicines, deep doctor relationships and aggressive rural distribution.
The Salesman Years: Where the Real Learning Happened
In 1974, Juneja began his career as a medical representative with KeePharma Ltd. A year later he joined Lupin Limited and worked as a first line manager for almost eight years.
Those years taught him more about India’s pharma ecosystem than any MBA ever could.
He travelled extensively in small towns and villages, often travelling long distances by public transport to see doctors and distributors. During this time he realised something that most big pharma companies ignored, rural India was massively under-served.
At that time, most pharma companies were heavily concentrating on metros and tier-1 cities. Small towns had poor distribution of medicine, fewer branded drug alternatives and very price sensitive consumers.
That observation later formed the basis of the Mankind Pharma rural market strategy.
Bestochem: The First Entrepreneurial Leap
Juneja quit Lupin in 1983 and started Bestochem with a group of partners.
Bestochem did reasonably well but Juneja left the company in 1994. The decision was a watershed as it opened the door to a much bigger goal.
But he chose to begin from scratch rather than to remain comfortable within an existing structure.
That willingness to reset would eventually lead to one of India’s greatest pharmaceutical success stories.
How Mankind Pharma Was Founded
Mankind Pharma was founded by Ramesh and Rajeev Juneja in 1995 with an initial investment of about ₹50 lakh. Reportedly, the organization started with about 25 medical salesmen who were focused on selling affordable healthcare supplies.
Their idea was simple but effective: the highest quality medicines should be affordable.
Unlike its peers, Mankind Pharma, focused on the “bottom of the pyramid” with branded pharmaceuticals 30-50% cheaper than the market leaders. The pricing strategy quickly set the company apart.
Mankind Pharma’s valuation grows about ₹4 crore within a year, a phenomenal performance for a young pharma company with operations outside India’s major cities.
The Rural-First Strategy That Changed Everything
Mankind Pharma’s success is attributed to its rural-first business model. The traditional heavyweights were concentrated in metropolitan hospitals and doctors in metros, while Mankind was aggressively foraying into tier-2, tier-3 and rural areas.
Mankind Pharma is apparently working with almost 16,000 stockists, 10,000 field staff and 22,000+ employees. Also it has 30 Production Facilities and Six centres of R&D.
This mammoth distribution network turned out to be the biggest competitive advantage for Mankind Pharma.
Rural pharma distribution in India is very difficult to replicate as it takes years of relationships with doctors, logistics optimization and community trust building.
Instead of fighting the big corporations on their ground, the Juneja brothers created new ground. That one move and Mankind Pharma became the leader of the market.
The Rise of Household Brands Like Prega News and Manforce
One of the smartest business moves by Mankind Pharma was entering the over-the-counter (OTC) segment. In 2007, the company launched consumer-focused healthcare brands that became household names.
OTC brands including:-
- Prega News
- Manforce
- Unwanted-72
- Gas-O-Fast
Mankind succeeded with these products combining low prices and heavyweight advertising.
While most Indian companies avoided open conversations around sexual wellness. Mankind aggressively promoted the category through TV advertising and celebrity campaigns, generating visibility and high margins. One of the most profitable verticals is consumer healthcare.
Mankind Pharma IPO: A Defining Milestone
The Mankind Pharma IPO in 2023 marked a major milestone in the company’s journey.
Key IPO Highlights
| Metric | Details |
| IPO Date | May 9, 2023 |
| IPO Size | ₹4,326 crore |
| IPO Price | ₹1,080 per share |
| QIB Subscription | 49.16x |
| Overall Subscription | 15.32x |
| Listing Day Gain | Around 32% |
Source:- Company annual reports, investor presentations, NSE filings, and publicly available reports
The IPO received massive investor interest, especially from institutional investors. Promoters did not treat it as an exit opportunity; instead, the company focused on long-term expansion and acquisitions, which strengthened investor confidence significantly.
Mankind Pharma Revenue and Financial Growth
Experts claim that the monetary expansion of Mankind Pharma throughout the previous years has reached a level that is highly remarkable. The Pharma company saw a large increase in wealth because it sold many products. The success of Mankind Pharma is acknowledged by many observers as it grew very fast.
FY25 Financial Performance
| Metric | FY25 Data |
| Revenue | ₹12,207 crore |
| Net Profit | ₹2,007 crore |
| Market Capitalisation | ~₹99,640 crore |
| Countries Exported To | 34 |
Source:- Company annual reports, investor presentations, NSE filings, and publicly available reports
When the third quarter of FY25 arrived, the revenue increased by 24% compared to the previous year. This expansion was produced by a high demand for medications that treat long-term sickness.
It has been observed that Mankind Pharma currently occupies the position of the fourth-biggest medical corporation in India based on sales within the country. The pharma-giant also holds the rank of second-largest company according to the total number of items sold.
The transformation of Mankind Pharma from a business that creates low-cost copies of medicines into a massive healthcare entity shows the overall growth of the Indian medicine sector.
The Bharat Serums Acquisition: The Next Big Move
During the year 2024, Mankind Pharma finished a purchase of Bharat Serums and Vaccines (BSV) for ₹13,630 crore. It is reported that the transaction was one of the largest purchases in the Indian pharmaceutical field recently. This transaction is regarded as a major event in the history of Mankind Pharma.
BSV specialises in:
- Gynaecology
- IVF treatments
- Critical care
- Emergency medicines
- Specialty biologics
This purchase of Bharat Serums and Vaccines (BSV) indicated a significant change in the business plan of the company. Many people believe that Mankind Pharma led the market for cheap generic medicines for a long time.
The Juneja-led form moved into the area of high-profit medical specialties because Bharat Serums and Vaccines (BSV) became part of Mankind Pharma. This period is frequently called the second growth chapter of the business.
Ramesh Juneja Net Worth 2026
Estimates from Forbes show that Ramesh Juneja possessed a total wealth of approximately $2.9 billion as of May 2026. Ramesh Juneja once worked as a medical representative who used public buses for travel. The journey of Ramesh Juneja becoming a billionaire demonstrates the huge possibilities for business people in India. It is understood that the progress of Mr. Juneja reflects the scale of the economy.
The family of Ramesh Juneja was placed among the wealthiest business groups in India. They have a total net worth of $9.7 billion. (Forbes)
Leadership and Family Structure at Mankind Pharma
A specific cause for the continuous expansion of the business is the organized way the company is led. Experts claim that the leadership model is the reason why Mankind Pharma can operate so well. Although the Juneja family is very active in the business, tasks are given to people based on their specific skills.
- Rajeev Juneja focuses on business plan growth.
- Arjun Juneja manages manufacturing and R&D.
- Sheetal Arora holds the role of CEO
This mixture of family ownership and working professionals helped Mankind Pharma grow in a very organized way.
Why the Mankind Pharma Story Matters
The victory of Ramesh Juneja is distinct because the achievement was built on knowledge of the market. The pharma-giant did not depend on expensive technology or money from outside investors.
Instead, Mankind Pharma succeeded through:-
- Affordable medicines
- Rural market penetration
- Strong doctor relationships
- Distribution strength
- Smart OTC branding
- Long-term execution
The Pharma company reached people in small villages because it has a very strong delivery network. This corporation represents a specific model of success that belongs to India. Mankind Pharma solves problems of the general population on a very large scale.
The change of Mankind Pharma from a small business into a subject studied by an educational institution like Harvard Business School shows that steady work leads to power.
FAQs
Who is the founder of Mankind Pharma?
Ramesh Juneja founded Mankind Pharma in 1995 along with his younger brother Rajeev Juneja.
What is Ramesh Juneja’s net worth in 2026?
Ramesh Juneja and the Juneja family reportedly had an estimated net worth of around $2.9 billion as of May 2026.
Why is Mankind Pharma successful?
Mankind Pharma became successful due to its affordable medicines strategy, rural market expansion, aggressive distribution network, and successful OTC brands like Prega News and Manforce.
What was the Mankind Pharma IPO size?
The Mankind Pharma IPO size was ₹4,326 crore and was launched in May 2023.
What is the Bharat Serums acquisition by Mankind Pharma?
In 2024, Mankind Pharma acquired Bharat Serums and Vaccines for approximately ₹13,630 crore to strengthen its specialty healthcare and biologics business.
How many countries does Mankind Pharma export to?
Mankind Pharma exports its products to 34 countries globally.
